Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Left atrial thrombosis in an anticoagulated patient after bioprosthetic valve replacement: Report of a case.

Literature DB >> 24527429

Left atrial thrombosis in an anticoagulated patient after bioprosthetic valve replacement: Report of a case.

Gian Marco Rosa¹, Antonello Parodi¹, Ulrico Dorighi¹, Federico Carbone¹, François Mach¹, Alessandra Quercioli¹, Fabrizio Montecucco¹, Nicolas Vuilleumier¹, Manrico Balbi¹, Claudio Brunelli¹.

Abstract

We present the case of a 74 year old woman suffering from severe mitral valve incompetence and rapid atrial fibrillation. After an appropriate vitamin K antagonist (VKA) therapy, the patient underwent mitral valve replacement by bioprosthesis. Then, the patient was re-hospitalized for jaundice. Suspecting hepatotoxicity, VKA was discontinued and fondaparinux was started. During this treatment, the patient developed a symptomatic atrial thrombus. After exclusion of a hepatic disease, VKA was re-established with hemodynamic and liver enzymes normalization and atrial thrombus resolution. Caution has to be used when considering fondaparinux as an alternative strategy to VKA in patients with multiple thrombotic risk factors.

Entities: Chemical Disease Species

Keywords: Atrium; Hepatotoxicity; Mitral valve; Prosthetic valve; Thrombus

Year: 2014 PMID： 24527429 PMCID： PMC3920233 DOI： 10.12998/wjcc.v2.i1.20

Source DB: PubMed Journal: World J Clin Cases ISSN： 2307-8960 Impact factor: 1.337

Keyword Cloud
References

9 in total

Review 1. Long-term performance of heart valve prostheses.

Authors: G L Grunkemeier; H H Li; D C Naftel; A Starr; S H Rahimtoola
Journal: Curr Probl Cardiol Date: 2000-02 Impact factor: 5.200

2. Guidelines on the management of valvular heart disease (version 2012).

Authors: Alec Vahanian; Ottavio Alfieri; Felicita Andreotti; Manuel J Antunes; Gonzalo Barón-Esquivias; Helmut Baumgartner; Michael Andrew Borger; Thierry P Carrel; Michele De Bonis; Arturo Evangelista; Volkmar Falk; Bernard Iung; Patrizio Lancellotti; Luc Pierard; Susanna Price; Hans-Joachim Schäfers; Gerhard Schuler; Janina Stepinska; Karl Swedberg; Johanna Takkenberg; Ulrich Otto Von Oppell; Stephan Windecker; Jose Luis Zamorano; Marian Zembala
Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983

3. Successful use of fondaparinux in a patient with a mechanical heart valve replacement and a history of heparin-induced thrombocytopenia.

Authors: Tia L Corbett; Kathy S Elher; Candice L Garwood
Journal: J Thromb Thrombolysis Date: 2010-10 Impact factor: 2.300

4. Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study.

Authors: Axel Schlitt; Kathrin Hamilton; Lars Maegdefessel; Manfred Dahm; Cathrin Theis; Michael Eichler; Olaf Brockmann; Ulrich Steinseifer; Baerbel Hauroeder; Walter E Hitzler; Hans J Rupprecht
Journal: J Heart Valve Dis Date: 2006-11

5. Clinical durability of the pericardial xenograft valve: ten years experience with mitral replacement.

Authors: M I Ionescu; D R Smith; S S Hasan; M Chidambaram; A P Tandon
Journal: Ann Thorac Surg Date: 1982-09 Impact factor: 4.330

6. Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model.

Authors: Axel Schlitt; Michael Buerke; Baerbel Hauroeder; Dirk Peetz; Ferdinand Hundt; Christoph Bickel; Iris Schaefer; Juergen Meyer; Hans J Rupprecht
Journal: Thromb Haemost Date: 2003-08 Impact factor: 5.249